Taisho Pharmaceutical Holdings Co., Ltd.
4581
Rang in aandelen
#3722
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Aandeelprijs
$54.31
Laatst gesynchroniseerd: 2024-04-08
Marktkapitalisatie
$4.45B
Verandering (1 dag)
-4.14%
Verandering (1 jaar)
0.00%
Land
JP
Handel Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Categorie
Healthcare
Operationele marge voor Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Operationele marge op October 2026 TTM: 7.64%
Volgens de meest recente financiële rapporten en aandelenkoers van Taisho Pharmaceutical Holdings Co., Ltd. is de huidige operationele marge (TTM) 7.64%. Eind 2022 had het bedrijf een operationele marge van 4.01%.
Geschiedenis van de operationele marge van Taisho Pharmaceutical Holdings Co., Ltd. van 2006 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 7.64% | 0.00% |
| 2023 | 7.64% | 90.52% |
| 2022 | 4.01% | -43.36% |
| 2021 | 7.08% | -4.71% |
| 2020 | 7.43% | -37.77% |
| 2019 | 11.94% | -9.55% |
| 2018 | 13.20% | 15.49% |
| 2017 | 11.43% | 14.76% |
| 2016 | 9.96% | -9.54% |
| 2015 | 11.01% | -21.80% |
| 2014 | 14.08% | 13.64% |
| 2013 | 12.39% | -12.50% |
| 2012 | 14.16% | -13.71% |
| 2011 | 16.41% | 22.28% |
| 2010 | 13.42% | -9.32% |
| 2009 | 14.80% | -19.30% |
| 2008 | 18.34% | 35.75% |
| 2007 | 13.51% | -37.31% |
| 2006 | 21.55% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 10.52% | -98.62% |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.00% |
IN
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.